Exploring Therapeutic Peptides in Orthopedic Science

A balanced look at what current research is uncovering about signaling molecules and musculoskeletal recovery.

Across regenerative and orthopedic medicine, scientists are studying how short chains of amino acids, known as peptides, help the body coordinate cellular communication and repair. These studies are part of a broader effort to understand how molecular pathways contribute to recovery after injury, surgery, or physical stress.

While some peptides are already FDA-approved for specific conditions (such as insulin or GLP-1 receptor agonists used in metabolic health), many others remain investigational. Researchers are exploring how these compounds interact with signaling systems that guide inflammation control, energy metabolism, and tissue remodeling.

The Basics: What Are Peptides?

Peptides are naturally occurring molecules built from amino acids, the same components that form proteins.
In laboratory and clinical settings, they are studied for their ability to “send messages” between cells, turning on or off specific biological processes. This signaling role makes them valuable research tools in exploring how tissues recover and adapt.

Modern orthopedic research looks at these signals in the context of wound healing, muscle repair, cartilage maintenance, and neurological recovery. The goal is not to replace surgery or rehabilitation, but to better understand the internal chemistry that drives healing.

What Scientists Are Investigating

Recent studies have focused on how certain peptides may influence biological systems such as:

• Vascular response and tissue repair — examining molecules that promote cell migration and microcirculation
• Inflammation and oxidative stress — exploring how peptides interact with immune signaling pathways
• Muscle and cartilage metabolism — studying how growth-related peptides might affect protein synthesis and matrix regulation
• Neuromuscular communication — researching how neuropeptides may support coordination and recovery through brain-muscle pathways
• Sleep and circadian rhythm — observing how naturally occurring peptides relate to hormonal balance and cellular regeneration

It is important to note that, while preclinical results (in cell or animal studies) are promising, human evidence remains limited, and most peptides under discussion are not approved by the U.S. Food and Drug Administration (FDA) for orthopedic or recovery use.

Safety, Oversight, and the Role of Regulation

Because peptides interact with biological signaling systems, responsible handling is essential.
Any use in a clinical context should occur under the guidance of a licensed healthcare professional and, when applicable, within an Institutional Review Board (IRB) or Investigational New Drug (IND) framework.

The FDA distinguishes between:

• Approved drug products (with established labeling and safety data)
• Compounded preparations made by licensed pharmacies for individual prescriptions under Section 503A of the Food, Drug, and Cosmetic Act
• Research-use materials, which are not for human administration

Understanding these distinctions helps protect both patients and providers while supporting legitimate research into recovery science.

Where the Field Is Headed

Interest in peptide research is growing quickly across regenerative medicine, sports science, and orthopedics. Researchers emphasize the importance of transparency, quality control, and data sharing as the field matures. Large, well-controlled human trials will be necessary to determine which peptides, if any, can be translated safely into approved medical use.

Until then, education and responsible communication remain essential. The Science of Recovery™ platform is committed to presenting peptide research in a way that informs, not promotes, encouraging open dialogue between clinicians, scientists, and the public.

 

References:

• Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12:141–146.
• DeFoor MT, Dekker TJ. Injectable therapeutic peptides—An adjunct to regenerative medicine and sports performance? Arthroscopy. 2025;41(2):150–152. doi:10.1016/j.arthro.2024.09.005.
• Fosgerau K, Hoffmann T. Peptide therapeutics: Current status and future directions. Drug Discov Today. 2015;20(1):122–128. doi:10.1016/j.drudis.2014.10.003.
• Wang L, Wang N, Zhang W, et al. Therapeutic peptides: Current applications and future directions. Signal Transduct Target Ther. 2022;7(1):48. doi:10.1038/s41392-022-00890-w.
• Anand U, Bandyopadhyay A, Jha NK, Pérez de la Lastra JM, Dey A. Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate. Biofactors. 2023;49(2):251–269. doi:10.1002/biof.1875.
• König D, Kohl J, Jerger S, Centner C. Potential relevance of bioactive peptides in sports nutrition. Nutrients. 2021;13(11):3997. doi:10.3390/nu13113997.
• Liu Q, Jia Z, Duan L, Xiong J, Wang D, Ding Y. Functional peptides for cartilage repair and regeneration. Am J Transl Res. 2018;10(2):501–510.
• Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(1):153–159. doi:10.1007/s00441-019-03016-6.
• Duzel A, Vlainic J, Antunovic M, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World J Gastroenterol. 2017;23(48):8465–8488. doi:10.3748/wjg.v23.i48.8465.
• Wang X, Liu B, Xu Q, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. 2018;25(2):270–278.
• Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in aging and longevity. Nat Rev Endocrinol. 2013;9(6):366–376. doi:10.1038/nrendo.2013.67.
• Geusens PP, Boonen S. Osteoporosis and the growth hormone–insulin-like growth factor axis. Horm Res. 2002;58(Suppl 3):49–55. doi:10.1159/000066483.
• Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527–1534. doi:10.1007/s00384-014-2030-8.
• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. doi:10.1530/eje.0.1390552.
• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. doi:10.1210/jc.2005-1536.
• Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone–releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150–158. doi:10.1210/jc.2010-1587.
• Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389. doi:10.1001/jama.2014.8334.
• Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291–4304.

Disclaimer

Science of Recovery™ provides educational information only and does not diagnose, treat, or endorse any medical product. Peptides described here are investigational and not approved by the U.S. Food and Drug Administration (FDA) for general therapeutic use. Always consult a licensed healthcare professional before considering any medical or nutritional intervention.